Tiziana Life Sciences is trading 6.3% down at $1.11, with no clear catalyst identified for the October 12, 2026 decline. - No specific company announcement explaining the decline was identified. - The investor-relations page lists the September 30 FDA orphan-drug designation filing as its latest press release, with no newer release shown. - Major indices are mixed, and none has moved more than 0.5% in the same direction as the stock.